Clinical Trials Logo

Pachyonychia Congenita clinical trials

View clinical trials related to Pachyonychia Congenita.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04520750 Active, not recruiting - Clinical trials for Pachyonychia Congenita

VALO-2: Study Evaluating the Safety and Efficacy of PTX022 in the Treatment of Adults With Pachyonychia Congenita

VALO-2
Start date: September 1, 2020
Phase: Phase 3
Study type: Interventional

VALO-2 is a multicenter, open-label extension (OLE) study enrolling patients with genotyped keratin mutations KRT6A, KRT6B and KRT16 who were previously treated with investigational PTX-022 during the VALO study. The purpose of the OLE study is to investigate long term exposure to investigational PTX-022 and evaluate safety and efficacy data. A sub-study is included to evaluate safety and efficacy of patients with genotyped keratin mutations of KRT6C and KRT17 not previously treated with investigational PTX-022.

NCT ID: NCT03920228 Active, not recruiting - Clinical trials for Pachyonychia Congenita

Phase 2/3 Study Evaluating the Safety and Efficacy of PTX-022 in Treatment of Adults With Pachyonychia Congenita

Start date: April 1, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

This study evaluates the safety and efficacy of PTX-022, topical rapamycin, in the treatment of adults with moderate to severe Pachyonychia Congenita. This study includes four-parts, and if a participant completes all parts, the participant will have received at least 3-months of PTX-022 treatment.